Trial readouts in the canine longevity space are about to start landing more frequently — multiple programmes have endpoints that will report out in the next eighteen months — and the public reporting that follows them will inevitably include some overstatement, some misinterpretation, and the occasional outright misleading framing. This is a short, practical guide to reading those readouts critically.

Start with what the trial was actually designed to detect. A 12-month trial powered to detect biomarker changes is not a trial that can tell you the drug extends lifespan. That doesn't mean the result is meaningless — biomarker improvements are how every drug class generates its first credible signal — but it does mean that any headline claiming "drug extends dogs' lives" based on a 12-month biomarker readout is jumping further than the data goes.

Look for the placebo arm. Without one, the result is interesting but not interpretable. Several recent veterinary geroscience trials have used historical control comparisons rather than concurrent placebo arms, often for legitimate practical reasons, but historical controls always raise the bar on how confident the conclusion can be.

Pay attention to dropout rates and the reasons behind them. A trial that loses 25% of its enrolled dogs over twelve months is not a trial that tells you much about long-term tolerability. A trial that loses 5% and reports the reasons transparently is a much stronger basis for inference.

Watch for selective endpoint reporting. The strongest readouts pre-register their primary endpoints and report all of them, even the ones that didn't reach significance. The weakest readouts emphasize whichever endpoint happened to look best after the fact. Pre-registered endpoint discipline is a meaningful quality signal.

Be suspicious of effect size language that doesn't include actual numbers. "Significantly improved" without a magnitude is meaningless — every randomized trial reaches statistical significance somewhere if you look hard enough. The question is always whether the effect is large enough to matter.

Finally, ignore stock price reactions and focus on the trial design and the data. Markets move on news; dogs do not. The right question is whether the result, if real, would meaningfully change what you'd do for your own dog. Most readouts in this category will not — they'll be incremental contributions to the larger picture rather than landmark moments. The genuinely landmark moments will be obvious in retrospect; in the moment, the most reliable signal is whether the trial was rigorous enough that the result deserves to stick.